Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × COVID-19 × selinexor × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 5 Recurrence 4 Neoplasms 2 Leukemia, Myeloid, Acute 2 Uterine Neoplasms 1 Uterine Diseases 1 Primary Myelofibrosis 1 Neoplasms by Site 1 Myeloproliferative Disorders 1 Lymphoma, Large B-Cell, Diffuse 1 Genital Diseases 1 Endometrial Neoplasms 1 COVID-19 1

Interventions

tocilizumab 1 selinexor 1 lenzilumab 1 cilgavimab and tixagevimab drug combination 1 Standard of Care 1 Practice Guidelines as Topic 1 Observation 1 Interferon-alpha 1 Immunoglobulin G 1 IMM-101 1 Disulfides 1 CVnCoV COVID-19 vaccine 1 COVID-19 Vaccines 1 BNT162 Vaccine 1 2019-nCoV Vaccine mRNA-1273 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04534725 2023-08-24

C-SMART

Peter MacCallum Cancer Centre, Australia

Phase 3 Completed

COVID-19, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡